Form 4: Vaxcyte CEO Grant Pickering Executes Stock Option, Sells Shares Under 10b5-1 Plan

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On August 23, 2024, Grant Pickering, the CEO of Vaxcyte, Inc., exercised a stock option to acquire 15,000 shares of common stock at a price of $2.03 per share.
• Simultaneously, Pickering sold 6,686 shares at a weighted average price of $78.651 and 8,314 shares at a weighted average price of $79.2526.
• These sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Pickering directly owns 478,888 shares of Vaxcyte common stock.
• He also indirectly owns 142,130 shares through a trust for his daughter and 142,130 shares through a trust for his son.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports transactions and doesn't convey any positive or negative outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially impacting the stock price.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common in the biopharmaceutical industry. Investors often monitor these transactions for insights into management's confidence in the company's prospects. The use of a 10b5-1 plan suggests a planned and orderly approach to selling shares.

Comparison to Industry Standards

• Comparing Grant Pickering's transactions to other CEOs in similar biotech companies, the scale of the sale is relatively modest.
• Many CEOs use 10b5-1 plans to diversify their holdings, especially after periods of significant stock appreciation.
• For example, the CEO of Moderna, Stéphane Bancel, has also utilized 10b5-1 plans to manage his stock holdings.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan may mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates